Dawn Baker
YOU?
Author Swipe
View article: Determining Adherence to Inhaled Corticosteroids From the Epic Electronic Medical Record
Determining Adherence to Inhaled Corticosteroids From the Epic Electronic Medical Record Open
OBJECTIVE Often we call the patient’s pharmacy to obtain a refill history to assess inhaled corticosteroid (ICS) adherence. The purpose of this project was to determine the accuracy of refill histories for ICS (with or without long-acting …
View article: supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and statistical analysis of cell lines treated with AZD4547 or DMSO over time
View article: supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
55 FGFR2 modified dynamic biomarker after treatment by AZD4547
View article: Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
The challenge of developing effective pharmacodynamic biomarkers for preclinical and clinical testing of FGFR signaling inhibition is significant. Assays that rely on the measurement of phospho-protein epitopes can be limited by the availa…
View article: supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Cell line panel used to identify AZD4547 dynamic transcript biomarkers.
View article: Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Supplementary figures S1: volcano plot of insensitive cell lines treated by AZD4547 S2:Immunohistochemistry of p-S6 and p-ERK tissue sections from xenograft treated with AZD4547 S3:FGFR pathway modulation in xenograft models treated with A…
View article: supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
View article: Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
The Notch signaling pathway has been implicated in cell fate determination and differentiation in many tissues. Accumulating evidence points toward a pivotal role in blood vessel formation, and the importance of the Delta-like ligand (Dll)…
View article: supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
View article: supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and two statistical analysis of ANC3A xenograft after treatment by AZD4547 and/or AZD5363 compared to vehicle group, and Combination group compared to singled agent.
View article: Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
The Notch signaling pathway has been implicated in cell fate determination and differentiation in many tissues. Accumulating evidence points toward a pivotal role in blood vessel formation, and the importance of the Delta-like ligand (Dll)…
View article: supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Gene symbol and primer ID used for targeted profiling on Fluidigm arrays
View article: Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
PDF file - 153K, Figure to support screening for antibodies
View article: supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and two statistical analysis of ANC3A xenograft after treatment by AZD4547 and/or AZD5363 compared to vehicle group, and Combination group compared to singled agent.
View article: Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Supplementary figures S1: volcano plot of insensitive cell lines treated by AZD4547 S2:Immunohistochemistry of p-S6 and p-ERK tissue sections from xenograft treated with AZD4547 S3:FGFR pathway modulation in xenograft models treated with A…
View article: supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Cell line panel used to identify AZD4547 dynamic transcript biomarkers.
View article: Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
PDF file - 98K
View article: supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and statistical analysis of cell lines treated with AZD4547 or DMSO over time
View article: supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
55 FGFR2 modified dynamic biomarker after treatment by AZD4547
View article: Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
PDF file - 153K, Figure to support screening for antibodies
View article: Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
The challenge of developing effective pharmacodynamic biomarkers for preclinical and clinical testing of FGFR signaling inhibition is significant. Assays that rely on the measurement of phospho-protein epitopes can be limited by the availa…
View article: supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
supplementary figures and tables legend
View article: supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
supplementary figures and tables legend
View article: Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> Open
PDF file - 98K
View article: supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Gene symbol and primer ID used for targeted profiling on Fluidigm arrays
View article: Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for whole human diagnostic cancer specimens.
View article: Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 2029K, Examples of tumour types classified as predominantly tumour vessel or stromal vessel phenotypes from TMA cores.
View article: Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 211K, Additional biomarker responses to DC101 in Calu-3 xenograft model.
View article: Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs. However, VEGF receptor (VEGFR) expression in human cancers, particularly the relat…
View article: Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 22K